All In MedTech

Device Trial Radar · NCT04559334

Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Actual

Start

Dec 21, 2020

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Boston Children's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
SterileCare Inc.
First posted
Sep 22, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 3 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this research study we want to learn more about a study drug, tetrasodium sodium EDTA (Kitelock™) for maintaining the patency (blood flow) through a central venous catheter. Catheter occlusions such as blood clots have been shown to increase the risk of central line-associated bloodstream infection (CLABSI). This treatment consists of instilling a daily a dose of a solution , similar to heparin or saline lock flushes, into the catheter when it is not in use. The aim is to prevent CLABSI without increasing complications such as catheter breakage.

Conditions

  • Central Line Complication
  • Central Line-associated Bloodstream Infection (CLABSI)

Interventions

  • Tetrasodium EDTA Catheter Lock SolutionDevice

    KiteLock™ 4% Sterile Catheter Lock Solution is a single use, clear, colorless and sterile solution. It is free of preservatives, alcohol and latex and is non-pyrogenic. KiteLock™ 4% is an aqueous solution containing a mixture of edetate tetrasodium and edetate trisodium. The solution composition is equivalent to 28 mg/mL edetate. EDTA is a known chelator. This means it has an affinity for metals and elements such as calcium. As a primary mechanism of action, it acts as a space occupying solution to prevent blood from entering the tip of the catheter when the catheter is not in use. As a secondary mechanism of action, it acts as an in vitro anticoagulant. This dual action decreases the risk of clot formation, consequently thrombolytic occlusions and by extension decreases the risk of CLABSI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Central Venous Catheter Occlusion Events During Tetrasodium EDTA Lock TherapyTime frame: 24 months before treatment initiation and 24 months after treatment initiation.
  2. Number of Central Venous Catheter Breakage Events During Tetrasodium EDTA Lock TherapyTime frame: 24 months before treatment initiation and 24 months after treatment initiation.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Childrens's Hospital Boston

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.